[{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tauroursodeoxycholic Acid","moa":"Apoptosis","graph1":"Neurology","graph2":"Phase II","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Morningside","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Series B Financing","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.029999999999999999,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Morningside","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Morningside"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tauroursodeoxycholic Acid","moa":"Apoptosis","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tauroursodeoxycholic Acid","moa":"","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tauroursodeoxycholic Acid","moa":"Apoptosis","graph1":"Neurology","graph2":"Phase II","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tauroursodeoxycholic Acid","moa":"Apoptosis","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Tauroursodeoxycholic Acid","moa":"Apoptosis","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tauroursodeoxycholic Acid","moa":"Apoptosis","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Tauroursodeoxycholic Acid","moa":"Apoptosis","graph1":"Neurology","graph2":"Phase II\/ Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"9","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Viking Global Investors","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Series C Financing","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0.14000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.14000000000000001,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Viking Global Investors","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Viking Global Investors"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Amylyx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Amylyx Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pharmaceuticals \/ Amylyx Pharmaceuticals"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"Mitochondria-mediated apoptosis","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Sunnybrook Research Institute","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Amylyx Pharmaceuticals \/ Sunnybrook Research Institute","highestDevelopmentStatusID":"4","companyTruncated":"Amylyx Pharmaceuticals \/ Sunnybrook Research Institute"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Goldman Sachs","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0.25,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.25,"dosageForm":"","sponsorNew":"Amylyx Pharmaceuticals \/ Goldman Sachs","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Goldman Sachs"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Goldman Sachs & Co.","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0.20999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0.20999999999999999,"dosageForm":"","sponsorNew":"Amylyx Pharmaceuticals \/ Goldman Sachs & Co.","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Goldman Sachs & Co."},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Neopharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Licensing Agreement","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amylyx Pharmaceuticals \/ Neopharm","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Neopharm"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder In Sachet","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Powder In Sachet","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Phase III","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Neurology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Powder In Sachet","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Eiger BioPharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Acquisition","leadProduct":"Avexitide","moa":"","graph1":"Endocrinology","graph2":"Phase II","graph3":"Amylyx Pharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Endocrinology","amount2New":0.040000000000000001,"dosageForm":"","sponsorNew":"Amylyx Pharmaceuticals \/ Amylyx Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"Amylyx Pharmaceuticals \/ Amylyx Pharmaceuticals"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Eiger BioPharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Acquisition","leadProduct":"Avexitide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Amylyx Pharmaceuticals \/ Amylyx Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Amylyx Pharmaceuticals"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Amylyx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Sodium Phenylbutyrate","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Amylyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Amylyx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amylyx Pharmaceuticals \/ Not Applicable"}]
Find Clinical Drug Pipeline Developments & Deals by Amylyx Pharmaceuticals
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
